|
1
|
Zhao J, Cheng M, Gai J, Zhang R, Du T and
Li Q: SPOCK2 serves as a potential prognostic marker and correlates
with immune infiltration in lung adenocarcinoma. Front Genet.
11:5884992020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun W, Feng J, Yi Q, Xu X, Chen Y and Tang
L: SPARC acts as a mediator of TGF-β1 in promoting
epithelial-to-mesenchymal transition in A549 and H1299 lung cancer
cells. Biofactors. 44:453–464. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang S, Jin J, Tian X and Wu L:
hsa-miR-29c-3p regulates biological function of colorectal cancer
by targeting SPARC. Oncotarget. 8:104508–104524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen H, Gu XH, Zhou Y, Ge Z, Wang B, Siok
WT, Wang G, Huen M, Jiang Y, Tan LH and Sun Y: A genome-wide
association study identifies genetic variants associated with
mathematics ability. Sci Rep. 7:403652017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang F, Zhang Y, Da J, Jia Z, Wu H and Gu
K: Downregulation of SPARC expression decreases cell migration and
invasion involving epithelial-mesenchymal transition through the
p-FAK/p-ERK pathway in esophageal squamous cell carcinoma. J
Cancer. 11:414–420. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang S, Xiang X, Liu L, Yang H, Cen D and
Tang G: Bioinformatics analysis of hub genes and potential
therapeutic agents associated with gastric cancer. Cancer Manag
Res. 13:8929–8951. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aghamaliyev U, Gaitantzi H, Thomas M,
Simon-Keller K, Gaiser T, Marx A, Yagublu V, Araos J, Cai C, Valous
NA, et al: Downregulation of SPARC is associated with
epithelial-mesenchymal transition and low differentiation state of
biliary tract cancer cells. Eur Surg Res. 60:1–12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Naczki C, John B, Patel C, Lafferty A,
Ghoneum A, Afify H, White M, Davis A, Jin G, Kridel S and Said N:
SPARC Inhibits metabolic plasticity in ovarian cancer. Cancers
(Basel). 10:3852018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Wang Y, Zheng G, Liu Y, Li J,
Huang H, Xu C, Zeng Y, Zhang X, Qin J, et al: Follistatin-like 1
(FSTL1) interacts with Wnt ligands and Frizzled receptors to
enhance Wnt/β-catenin signaling in obstructed kidneys in vivo. J
Biol Chem. 298:1020102022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen L, Zhou SJ, Xu Y, Liao QM, Zou YS and
Pei H: CCAR2 promotes a malignant phenotype of osteosarcoma through
Wnt/β-catenin-dependent transcriptional activation of SPARC.
Biochem Biophys Res Commun. 580:67–73. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye Z, Chen J, Hu X, Yang S, Xuan Z, Lu X
and Zhao Q: SPOCK1: A multi-domain proteoglycan at the crossroads
of extracellular matrix remodeling and cancer development. Am J
Cancer Res. 10:3127–3137. 2020.PubMed/NCBI
|
|
12
|
Bhat AA, Wani HA, Ishaq S, Waza AA, Malik
RA, Shabir I, Jeelani S, Kadla S, Qureshie W, Masood A and Majid S:
Promoter hypermethylation and its impact on expression of MGMT gene
in the GIT malignant patients of Kashmiri origin. Cancer Invest.
35:116–121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. PLoS Med. 18:e10035832021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fabrizio FP, Sparaneo A, Fontana A, Mazza
T, Graziano P, Pantalone A, Parente P, Centra F, Orlando N,
Trombetta D, et al: Potential prognostic role of SPARC methylation
in non-small-cell lung cancer. Cells. 9:15232020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao M, Hu Q and Li C: Effects of
overexpression of cysteine-rich acidic secreted protein on the
sensitivity of albumin binding paclitaxel in non-small cell lung
cancer cells. Chin Med. 15:52020.
|
|
17
|
Andriani F, Landoni E, Mensah M,
Facchinetti F, Miceli R, Tagliabue E, Giussani M, Callari M, De
Cecco L, Colombo MP, et al: Diagnostic role of circulating
extracellular matrix-related proteins in non-small cell lung
cancer. BMC Cancer. 18:8992018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li X, Kabolizadeh P, Yan D, Qin A, Zhou J,
Hong Y, Guerrero T, Grills I, Stevens C and Ding X: Improve
dosimetric outcome in stage III non-small-cell lung cancer
treatment using spot-scanning proton arc (SPArc) therapy. Radiat
Oncol. 13:352018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duan J, Hao Y, Wan R, Yu S, Bai H, An T,
Zhao J, Wang Z, Zhuo M and Wang J: Efficacy and safety of weekly
intravenous nanoparticle albumin-bound paclitaxel for non-small
cell lung cancer patients who have failed at least two prior
systemic treatments. Thorac Cancer. 8:138–146. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Komiya K, Nakamura T, Nakashima C,
Takahashi K, Umeguchi H, Watanabe N, Sato A, Takeda Y, Kimura S and
Sueoka-Aragane N: SPARC is a possible predictive marker for
albumin-bound paclitaxel in non-small-cell lung cancer. Onco
Targets Ther. 9:6663–6668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng PF, Han FC, Guo QX, Wang J, Shan BB
and Zhang F: Progress of SPARC and albumin-bound paclitaxel in
non-small cell lung cancer. Chin J Cliicians (Electronic Edition).
10:2136–2140. 2016.(In Chinese).
|
|
22
|
Kurtul N, Eroglu C, Unal D, Tasdemir EA,
Orhan O, Zararsiz G, Baran M, Kaplan B and Kontas O: Prognostic
value of SPARC expression in unresectable NSCLC treated with
concurrent chemoradiotherapy. Asian Pac J Cancer Prev.
15:8911–8916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grant JL, Fishbein MC, Hong LS, Krysan K,
Minna JD, Shay JW, Walser TC and Dubinett SM: A novel molecular
pathway for Snail-dependent, SPARC-mediated invasion in non-small
cell lung cancer pathogenesis. Cancer Prev Res (Phila). 7:150–160.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yin H, Wang Y, Chen W, Zhong S, Liu Z and
Zhao J: Drug-resistant CXCR4-positive cells have the molecular
characteristics of EMT in NSCLC. Gene. 594:23–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang ZP, Wang Z, Liu XY, Shi M, Chen G,
Zhang B, Li Z and Song L: Correlation of KLF4 and SPARC expression
with the clinical characteristics of non-small cell lung cancer.
Zhongguo Fei Ai Za Zhi. 15:720–724. 2012.(In Chinese). PubMed/NCBI
|
|
26
|
Huang Y, Zhang J, Zhao YY, Jiang W, Xue C,
Xu F, Zhao HY, Zhang Y, Zhao LP, Hu ZH, et al: SPARC expression and
prognostic value in non-small cell lung cancer. Chin J Cancer.
31:541–548. 2012.PubMed/NCBI
|
|
27
|
Ma YG, Lou Y and Zhao HR: Study on
expression and promoter methylation of Apaf-1 gene in non-small
cell lung cancer. Chin J Cancer Prev Treat. 13:116–119. 2006.(In
Chinese).
|
|
28
|
Koukourakis MI, Giatromanolaki A, Brekken
RA, Sivridis E, Gatter KC, Harris AL and Sage EH: Enhanced
expression of SPARC/osteonectin in the tumor-associated stroma of
non-small cell lung cancer is correlated with markers of
hypoxia/acidity and with poor prognosis of patients. Cancer Res.
63:5376–5380. 2003.PubMed/NCBI
|
|
29
|
Zheng Y, Tang J, Zhang Z, Zhang Z, Zhang X
and Feng P: Expression and significance of SPARC and TGFβ1 in lung
cancer. Cancer Prev Treat Res. 41:593–597. 2014.
|
|
30
|
Zheng YJ, Zhang ZH, Zhang XL, Tang JH,
Zhang ZL and Feng P: Expression and significance of SPARC and CD105
in lung cancer tissues. Shandong Medicine. 55:64–65. 2015.(In
Chinese).
|
|
31
|
Xu J, Yang S, Gu X, Shen H, Wang L, Xu W,
Fang L, Mao Y, Xu L, Chen Y, et al: SPARC correlates with
unfavorable outcome and promotes tumor growth in lung squamous cell
carcinoma. Exp Mol Pathol. 110:1042762019.(In Chinese). View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yan J, Zhang J, Zhang X, Li X, Li L, Li Z,
Chen R, Zhang L, Wu J, Wang X, et al: SPARC is down-regulated by
DNA methylation and functions as a tumor suppressor in T-cell
lymphoma. Exp Cell Res. 364:125–132. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wong SL and Sukkar MB: The SPARC protein:
An overview of its role in lung cancer and pulmonary fibrosis and
its potential role in chronic airways disease. Br J Pharmacol.
174:3–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
John B, Naczki C, Patel C, Ghoneum A,
Qasem S, Salih Z and Said N: Regulation of the bi-directional
cross-talk between ovarian cancer cells and adipocytes by SPARC.
Oncogene. 38:4366–4383. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma J, Gao S, Xie X, Sun E, Zhang M, Zhou Q
and Lu C: SPARC inhibits breast cancer bone metastasis and may be a
clinical therapeutic target. Oncol Lett. 14:5876–5882.
2017.PubMed/NCBI
|
|
36
|
Yu XZ, Guo ZY, Di Y, Yang F, Ouyang Q, Fu
DL and Jin C: The relationship between SPARC expression in primary
tumor and metastatic lymph node of resected pancreatic cancer
patients and patients' survival. Hepatobiliary Pancreat Dis Int.
16:104–109. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Murakawa M, Aoyama T, Miyagi Y, Kobayashi
S, Ueno M, Morimoto M, Numata M, Yamamoto N, Tamagawa H, Yukawa N,
et al: The impact of SPARC expression on the survival of pancreatic
ductal adenocarcinoma patients after curative resection. J Cancer.
10:627–633. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hung JY, Yen MC, Jian SF, Wu CY, Chang WA,
Liu KT, Hsu YL, Chong IW and Kuo PL: Secreted protein acidic and
rich in cysteine (SPARC) induces cell migration and epithelial
mesenchymal transition through WNK1/snail in non-small cell lung
cancer. Oncotarget. 8:63691–63702. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu G, Zhao L, Qin A, Grills I,
Deraniyagala R, Stevens C, Zhang S, Yan D, Li X and Ding X: Lung
stereotactic body radiotherapy (SBRT) using spot-scanning proton
Arc (SPArc) therapy: A feasibility study. Front Oncol.
11:6644552021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li C, Hou X, Yuan S, Zhang Y, Yuan W, Liu
X, Li J, Wang Y, Guan Q and Zhou Y: High expression of TREM2
promotes EMT via the PI3K/AKT pathway in gastric cancer:
Bioinformatics analysis and experimental verification. J Cancer.
12:3277–3290. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yao L, Zhou Y, Li J, Wickens L, Conforti
F, Rattu A, Ibrahim FM, Alzetani A, Marshall BG, Fletcher SV, et
al: Bidirectional epithelial-mesenchymal crosstalk provides
self-sustaining profibrotic signals in pulmonary fibrosis. J Biol
Chem. 297:1010962021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bertino EM, Williams TM, Nana-Sinkam SP,
Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS,
Villalona-Calero MA and Otterson GA: Stromal caveolin-1 is
associated with response and survival in a phase II trial of
nab-paclitaxel with carboplatin for advanced NSCLC patients. Clin
Lung Cancer. 16:466–474. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Toyota K, Murakami Y, Kondo N, Uemura K,
Nakagawa N, Takahashi S and Sueda T: Impact of secreted protein
acidic and rich in cysteine (SPARC) expression on prognosis after
surgical resection for biliary carcinoma. J Gastrointest Surg.
21:990–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ma Y, Zhu J, Chen S, Ma J, Zhang X, Huang
S, Hu J, Yue T, Zhang J, Wang P, et al: Low expression of SPARC in
gastric cancer-associated fibroblasts leads to stemness
transformation and 5-fluorouracil resistance in gastric cancer.
Cancer Cell Int. 19:1372019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Siddiqui MA, Gollavilli PN, Ramesh V,
Parma B, Schwab A, Vazakidou ME, Natesan R, Saatci O, Rapa I,
Bironzo P, et al: Thymidylate synthase drives the phenotypes of
epithelial-to-mesenchymal transition in non-small cell lung cancer.
Br J Cancer. 124:281–289. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang B and Zhang Z, Tang J, Tao H and
Zhang Z: Correlation between SPARC, TGFβ1, Endoglin and
angiogenesis mechanism in lung cancer. J Biol Regul Homeost Agents.
32:1525–1531. 2018.PubMed/NCBI
|
|
47
|
Wan S, Meyer AS, Weiler SME, Rupp C, Tóth
M, Sticht C, Singer S, Thomann S, Roessler S, Schorpp-Kistner M, et
al: Cytoplasmic localization of the cell polarity factor scribble
supports liver tumor formation and tumor cell invasiveness.
Hepatology. 67:1842–1856. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dimas DT, Perlepe CD, Sergentanis TN,
Misitzis I, Kontzoglou K, Patsouris E, Kouraklis G, Psaltopoulou T
and Nonni A: The prognostic significance of Hsp70/Hsp90 expression
in breast cancer: A systematic review and meta-analysis. Anticancer
Res. 38:1551–1562. 2018.PubMed/NCBI
|
|
49
|
Alcaraz LB, Mallavialle A, David T, Derocq
D, Delolme F, Dieryckx C, Boissière-Michot F, Simony-Lafontaine J,
du Manoir S, Huesgen PF, et al: Cathepsin D exacerbates
SPARC-driven aggressiveness by limited proteolysis in
triple-negative breast cancer. bioRxiv. 2020.
|
|
50
|
Poomsawat S, Kosanwat T, Meesakul O and
Sanguansin S: Epithelial and fibroblast SPARC expression patterns
in oral leukoplakia and oral squamous cell carcinoma. Oral Surg
Oral Med Oral Pathol Oral Radiol. 134:e44–e50. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gao ZW, Liu C, Yang L, He T, Wu XN, Zhang
HZ and Dong K: SPARC overexpression promotes liver cancer cell
proliferation and tumor growth. Front Mol Biosci. 8:7757432021.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sanità G, Armanetti P, Silvestri B,
Carrese B, Calì G, Pota G, Pezzella A, d'Ischia M, Luciani G,
Menichetti L and Lamberti A: Albumin-modified melanin-silica hybrid
nanoparticles target breast cancer cells via a SPARC-dependent
mechanism. Front Bioeng Biotechnol. 8:7652020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kehlet SN, Manon-Jensen T, Sun S, Brix S,
Leeming DJ, Karsdal MA and Willumsen N: A fragment of SPARC
reflecting increased collagen affinity shows pathological relevance
in lung cancer-implications of a new collagen chaperone function of
SPARC. Cancer Biol Ther. 19:904–912. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xing P, Zhu Y, Shan L, Chen S, Hao X and
Li J: The role of weekly nanoparticle albumin bound paclitaxel
monotherapy as second line or later treatment for advanced NSCLC in
China. Oncotarget. 8:87442–87454. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Croci GA, Au-Yeung RKH, Reinke S, Staiger
AM, Koch K, Oschlies I, Richter J, Poeschel V, Held G, Loeffler M,
et al: SPARC-positive macrophages are the superior prognostic
factor in the microenvironment of diffuse large B-cell lymphoma and
independent of MYC rearrangement and double-/triple-hit status. Ann
Oncol. 32:1400–1409. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang X, Xie J, Sun H, Wei Q and Nong G:
miR-29a-3p regulates the epithelial-mesenchymal transition via the
SPARC/ERK signaling pathway in human bronchial epithelial cells.
Int J Mol Med. 48:1712021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Alcaraz LB, Mallavialle A, David T, Derocq
D, Delolme F, Dieryckx C, Mollevi C, Boissière-Michot F,
Simony-Lafontaine J, Du Manoir S, et al: A 9-kDa matricellular
SPARC fragment released by cathepsin D exhibits pro-tumor activity
in the triple-negative breast cancer microenvironment.
Theranostics. 11:6173–6192. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Paulsson J and Micke P: Prognostic
relevance of cancer-associated fibroblasts in human cancer. Semin
Cancer Biol. 25:61–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ghanemi A, Yoshioka M and St-Amand J:
Measuring exercise-induced secreted protein acidic and rich in
cysteine expression as a molecular tool to optimize personalized
medicine. Genes (Basel). 12:18322021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ghanemi A, Yoshioka M and St-Amand J:
Secreted protein acidic and rich in cysteine as a molecular
physiological and pathological biomarker. Biomolecules.
11:16892021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Veith C, Vartürk-Özcan I, Wujak M, Hadzic
S, Wu CY, Knoepp F, Kraut S, Petrovic A, Gredic M, Pak O, et al:
SPARC, a novel regulator of vascular cell function in pulmonary
hypertension. Circulation. 145:916–933. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yuan S, Xu J, Zhou B, Zhou Y, Lang M, Cao
J, Liu Z, Yang S, Gao S and Hao J: SOX8 affects tumoral SPARC
expression by regulating EZH2 to attenuate effectiveness of
albumin-bound paclitaxel in PDAC. Int J Biol Sci. 18:911–922. 2022.
View Article : Google Scholar : PubMed/NCBI
|
